Atherosclerosis 150 (2000) 461 – 462
Subject index
Volume 150 (2000)
www.elsevier.com/locate/atherosclerosis
Abdominal obesity 150, 135
ACE 150, 21
Acetylhydrolase 150, 209
Adhesion molecule 150, 265
Adhesion molecules 150, 33
Adults 150, 201
Ageing 150, 209
Aggregated LDL 150, 91
Aggregation 150, 91
Aminoguanidine 150, 299 Angiography 150, 371 Angiotensin-II 150, 21 Antioxidants 150, 299, 381, 403
Aorta 150, 321
Apolipoprotein A-I 150, 113, 201
Apolipoprotein A-IV 150, 187
Apolipoprotein B-100 150, 167
Apolipoprotein B-48 150, 167
Apolipoprotein B 150, 255
Apolipoprotein C-III 150, 149
Apolipoprotein E 150, 71, 91 Apolipoprotein E phenotype 150, 167 Apoptosis 150, 309
Arterial wall 150, 91
Artery 150, 245
Ascorbic acid 150, 275
Atherogenesis 150, 21, 343
Atherosclerosis 150, 21, 55, 63, 71, 81, 91, 167, 209, 217, 245, 285,
321, 371
Atorvastatin 150, 421
Autoantibodies 150, 403
Balloon injury 150, 309 Bezafibrate 150, 429 Bilirubin 150, 381
Bone marrow transplantation 150, 71
Breath test 150, 13
Calcium 150, 357
Carbohydrate 150, 159, 227
Cardiovascular risk factors 150, 397
Carotenoids 150, 265
Carotid arteries 150, 371
Carotid artery 150, 397 CD143 150, 21 Cell death 150, 331 Cerebral infarction 150, 209
Cholesterol 150, 149, 381
Cholesterol-lowering drugs 150, 113
Cholesterol synthesis 150, 421
Cholesteryl ester 150, 13
Cholesteryl ester transfer activity 150, 129 Chylomicron remnants 150, 13
Combination 150, 103 Combination therapy 150, 429
Coronary 150, 321
Coronary artery disease 150, 159, 381, 413
Coronary disease 150, 193, 371
Coronary heart disease 150, 179, 275, 295, 403
Cytokines 150, 33, 63
Diabetes 150, 227 Diabetes mellitus 150, 193 Diet 150, 227
DNA polymorphism 150, 187
D2 vitamin 150, 55
Dyslipidemia 150, 149
ELISA 150, 343
Endothelial cell 150, 265
Endothelin-1 150, 43
17b-Estradiol 150, 201
17b-estradiol 150, 275 Estrogen 150, 103, 275 Exercise 150, 193 Fatty acids 150, 227
Femoral artery 150, 397
Fibrinogen 150, 365
Fluvastatin 150, 429
Genes 150, 179, 193
Genetic polymorphism 150, 295 Genetics 150, 135, 143, 149 Glucose 150, 227
Glycated lipoprotein(a) 150, 299
Glycosylated haemoglobin 150, 121
Glycoxidation of LDL 150, 343
Growth factors 150, 63
HDL 150, 159
HDL-C 150, 187
HDL-cholesterol 150, 381
Hemodialysis 150, 217 Hepatectomized 150, 13 High-density lipoprotein 150, 103 Homocysteine 150, 179
Homozygous familial hypercholesterolaemia 150, 421
Subject index6ol.150 (2000) 462
Human hepatoma cells 150, 255 Human saphenous vein 150, 33
Hypercholesterolemia 150, 55, 81, 149, 309 Hyperlipidaemia 150, 429
Hypertension 150, 193
Hypertriglyceridemia 150, 149
Immunohistochemistry 150, 343 Infarction 150, 81
Innervation 150, 43 Insulin 150, 227, 365
Insulin resistance 150, 55, 121, 159
Insulin sensitivity 150, 365
Intima – media thickness 150, 397
In vivo kinetics 150, 113 Ischemic stroke 150, 389
LDL 150, 159, 285
LDL cholesterol 150, 429
Lipid metabolism 150, 201
Lipid peroxidation 150, 217, 295, 403
Lipoprotein(a) 150, 201 Lipoprotein (a) 150, 389
Lipoprotein-associated phospholipase A2 150, 413
Lipoprotein lipase 150, 135, 357
Lipoprotein oxidation 150, 129
Lipoproteins 150, 71, 149, 403
Low-density lipoprotein 150, 103, 217
Low density lipoprotein 150, 357
Low-density lipoprotein 150, 275
Lycopene 150, 265
Macrophages 150, 71, 91, 357 Magnetic resonance imaging 150, 321
Male aortic endothelial cells 150, 275
Malondialdehyde 150, 403
Matrix metalloproteinases 150, 245
Metabolic syndrome 150, 365 Metabolism 150, 13
Methyl palmoxirate 150, 13 Mevalonic acid 150, 421
Middle-aged cigarette smokers 150, 397
Minimal model 150, 365
Monocytes 150, 63
Monounsaturated fat 150, 159, 227 Monounsaturated fatty acids 150, 255
Mouse 150, 285
Myocardial infarction 150, 143, 209
No-(carboxymethyl)lysine (CML)-protein adduct 150, 343
Neointima 150, 33
Nitric oxide 150, 179
Non-insulin dependent diabetes mellitus 150, 121
Norethisterone 150, 201 Obesity 150, 187
Oxidation 150, 285, 357
Oxidized phosphatidylcholine 150, 343
Oxidized phospholipids 150, 209
p53 150, 309, 331
Paraoxonase 150, 295
Peripheral arterial disease 150, 179
Peritoneal dialysis 150, 217
Plaque rupture 150, 245
Plasminogen activator inhibitor-1 150, 299
Platelet 150, 143
Platelet-activating factor 150, 209
Polymorphism 150, 149
Polyunsaturated 150, 285
Polyunsaturated fat 150, 227
Polyunsaturated fatty acids 150, 255 Porcine 150, 321
Postmenopausal women 150, 103
Postprandial lipemia 150, 167
Potential new risk factor 150, 413
Preconditioning 150, 81
Prediction 150, 381 Proliferation 150, 309, 331
Protective lipid profile 150, 135
Proteoglycans 150, 91
Quantitative coronary angiography 150, 167 Remnant-like emulsions 150, 13
Remodeling 150, 245
Renal failure 150, 217
Respiratory quotient 150, 121 Restenosis 150, 309
Risk factors 150, 143, 381
Safflower oil 150, 285
Sand rat 150, 55
Saturated fat 150, 227 Saturated fatty acids 150, 255
Simvastatin 150, 103
Smoking 150, 193
Smooth muscle 150, 63
Smooth muscle cells 150, 331 Stable isotopes 150, 113 Statins 150, 121
Stroke in the young 150, 389
SV40 large TAg 150, 331
Tissue-type plasminogen activator 150, 299 a-Tocopherol 150, 217
Triglyceride 150, 429
Triglyceride-rich lipoproteins 150, 167
Triglycerides 150, 149
Turner Syndrome 150, 201 Type 2 diabetes mellitus 150, 167
U937 150, 265
Ultrasonography 150, 371, 397
Vascular endothelial cells 150, 299 Vein grafts 150, 43
Very low-density lipoprotein 150, 103
Vitamin E 150, 129
Weight loss 150, 187
